Patents Assigned to Amgen
  • METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING ANTAGONISTIC BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR)/GLP-1 RECEPTOR AGONIST FUSION PROTEINS
    Publication number: 20200384119
    Abstract: Method of treating metabolic diseases and disorders using a composition comprising a GLP-1/GIPR antigen binding protein fusion protein are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises the C-terminus of a GLP-1 analog fused to the N-terminus of the light chain variable or heavy chain variable region of an antibody or functional fragment thereof that binds GIPR, optionally with a linker in between.
    Type: Application
    Filed: June 20, 2018
    Publication date: December 10, 2020
    Applicant: AMGEN INC.
    Inventors: Kenneth W. WALKER, Jerry Ryan HOLDER, David J. LLOYD, Shu-Chen LU, MurIelle M. VENIANT-ELLISON, Shanaka STANISLAUS
  • Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane
    Patent number: 10857229
    Abstract: Methods and compositions for treating ovarian cancer in a human patient with ascites by administering a therapeutically effective amount of an Ang2 inhibitor in combination with a taxane.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: December 8, 2020
    Assignee: Amgen Inc.
    Inventors: Bruce Allen Bach, Florian Vogl
  • Solution phase method for preparing etelcalcetide
    Patent number: 10858389
    Abstract: The instant disclosure is directed to solution phase fragment coupling methods for preparing etelcalcetide and its pharmaceutically acceptable salts.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: December 8, 2020
    Assignee: Amgen Inc.
    Inventors: Sheng Cui, Krishnakumar Ranganathan, Richard Crockett, Ying Chen, Aleksander Swietlow, Kevin Crossley, Yun Shi, Karel Decroos, Etienne Moniotte
  • Pegylated Carfilzomib Compounds
    Publication number: 20200376131
    Abstract: The present invention provides a method of treating multiple myeloma using polymeric pegylated carfilzomib compounds, and pharmaceutically acceptable salts thereof, of Formula I wherein R1, R2, linker, PEG, n and o are as defined herein.
    Type: Application
    Filed: April 23, 2020
    Publication date: December 3, 2020
    Applicant: AMGEN INC.
    Inventors: Gary LUEHR, Shabbir T. ANIK, Ge PENG, Irina DOTSENKO, Pasit PHIASIVONGSA, Dante ROMANINI
  • Antibody constructs for CD70 and CD3
    Patent number: 10851170
    Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human CD70 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: December 1, 2020
    Assignees: AMGEN RESEARCH (MUNICH) GMBH, AMGEN INC.
    Inventors: Tobias Raum, Claudia Blümel, Wibke Deisting, Patrick Hoffmann, Ralf Lutterbüse, Elisabeth Nahrwold, Olivier Nolan-Stevaux, Marc Panzer
  • Injector and method of assembly
    Patent number: 10850037
    Abstract: An injector may include a container having a wall with an interior surface defining a closed sterile reservoir filled with a drug product. The injector may also include a fluid delivery system comprising a sterile container needle that is in fluid communication with the container in a delivery state, but may or may not be in fluid communication with the container in a storage state. Further, the injector may include an actuator that is adapted to move the container needle from the storage state to the delivery state.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: December 1, 2020
    Assignee: AMGEN INC.
    Inventor: Scott R. Gibson
  • Interleukin-2 muteins for the expansion of T-regulatory cells
    Patent number: 10851144
    Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: December 1, 2020
    Assignee: Amgen Inc.
    Inventors: Eric Alan Butz, Christy Ann Thomson, Marc Alain Gavin, Ian Nevin Foltz, Dong Xia, Dina N. Alcorn, Ai Ching Lim, Randal Robert Ketchum, Kathy Manchulenko, Laura Sekirov, Kelly Ann Berry, Cyr Clovis Chua De Imus, Neeraj Jagdish Agrawal, Gunasekaran Kannan, Li Li
  • SOLID STATE FORMS
    Publication number: 20200369662
    Abstract: The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.
    Type: Application
    Filed: May 20, 2020
    Publication date: November 26, 2020
    Applicant: AMGEN INC.
    Inventors: Mary CHAVES, Patricia LOPEZ, Prashant AGARWAL, Albert AMEGADZIE, Stephanie AZALI, Roman SHIMANOVICH, Ron C. KELLY, Darren Leonard REID
  • DOSING OF KRAS INHIBITOR FOR TREATMENT OF CANCERS
    Publication number: 20200360374
    Abstract: Provided herein are methods of administering a KRAS G12C inhibitor to a cancer subject.
    Type: Application
    Filed: May 13, 2020
    Publication date: November 19, 2020
    Applicant: AMGEN INC.
    Inventors: Haby HENARY, James Russell LIPFORD, Victor J. CEE
  • METHOD OF TREATING IDIOPATHIC THROMBOCYTOPENIA PURPURA (ITP) WITH ROMIPLOSTIM
    Publication number: 20200360480
    Abstract: The present invention concerns a method of treating idiopathic thrombocytopenia purpura (ITP) in a patient having ITP, which comprises: (a) administering romiplostim weekly to the patient; (b) increasing the weekly dose until a platelet count of at least about 50 to 200×109/L is reached; (c) decreasing the weekly dose of romiplostim if the platelet count remains ?200×109/L for two consecutive weeks; (d) discontinuing romiplostim if the platelet count has remained ?200×109/L for two consecutive weeks when the weekly dose is 1 ?g/kg or the platelet count is ?400×109/L; and (e) if a platelet count ?200×109/L is reached within the first 4 to 12 weeks of treatment, maintaining a treatment-free period of at least about 24 weeks during which the patient receives no romiplostim.
    Type: Application
    Filed: December 6, 2018
    Publication date: November 19, 2020
    Applicant: AMGEN INC.
    Inventors: Michael TARANTINO, James BUSSEL, Melissa EISEN, Nancy CARPENTER, Xuena WANG, Susanna MAC
  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20200360399
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: August 17, 2018
    Publication date: November 19, 2020
    Applicant: AMGEN INC.
    Inventors: Sean P. BROWN, Kexue LI, Yunxiao LI, Anthony B. REED, Brian Alan LANMAN
  • Thermal spring release mechanism for a drug delivery device
    Patent number: 10835685
    Abstract: A spring release mechanism for a drug delivery includes a fusible member to restrain a spring in a charged state. A heating element is utilized to selectively heat and sever the fusible member. When the fusible member is severed, the spring is allowed to discharge and drive the drug delivery device components operably coupled thereto.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: November 17, 2020
    Assignee: AMGEN INC.
    Inventor: Lawrence Scott Ring
  • Compounds that inhibit MCL-1 protein
    Patent number: 10836779
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: November 17, 2020
    Assignee: AMGEN INC.
    Inventors: Sean P. Brown, Yunxiao Li, Mike Elias Lizarzaburu, Brian S. Lucas, Nick A. Paras, Joshua Taygerly, Marc Vimolratana, Xianghong Wang, Ming Yu, Manuel Zancanella, Liusheng Zhu, Ana Gonzalez Buenrostro, Zhihong Li
  • EXCIPIENTS TO REDUCE THE VISCOSITY OF ANTIBODY FORMULATIONS AND FORMULATION COMPOSITIONS
    Publication number: 20200352857
    Abstract: This invention concerns a series of excipients capable of effectively reducing the viscosity of protein formulations. The viscosity reducing excipients are oligopeptides (e.g., dipeptides, tripeptides) comprising at least one arginine. The peptides may also include basic or acidic or hydrophilic or hydrophobic/aromatic amino acids. An arginine residue may be either at the amino or the carboxyl end of the oligopeptide.
    Type: Application
    Filed: April 24, 2018
    Publication date: November 12, 2020
    Applicant: AMGEN INC.
    Inventors: Jian Hua GU, Robert Matthew FESINMEYER, Rulin QIAN
  • ANTIBODIES TO OPGL
    Publication number: 20200354464
    Abstract: Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.
    Type: Application
    Filed: June 18, 2020
    Publication date: November 12, 2020
    Applicants: AMGEN INC., AMGEN FREMONT INC.
    Inventors: William J. BOYLE, Francis H. MARTIN, Jose R. CORVALAN, C. Geoffrey DAVIS
  • Interleukin-2 muteins for the expansion of T-regulatory cells
    Patent number: 10829535
    Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: November 10, 2020
    Assignee: Amgen Inc.
    Inventors: Marc A. Gavin, Gunasekaran Kannan, Li Li, Joshua T. Pearson, Margaret Karow
  • Methods and apparati for nondestructive detection of undissolved particles in a fluid
    Patent number: 10832433
    Abstract: The apparati, methods, and computer program products disclosed herein can be used to nondestructively detect undissolved particles, such as glass flakes and/or protein aggregates, in a fluid in a vessel, such as, but not limited to, a fluid that contains a drug.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: November 10, 2020
    Assignee: AMGEN INC.
    Inventors: Graham F. Milne, Erwin Freund, Ryan L. Smith
  • Methods for modulating mannose content of recombinant proteins
    Patent number: 10829551
    Abstract: The present invention relates to methods of modulating (e.g., reducing) the mannose content, particularly high-mannose content of recombinant glycoproteins.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: November 10, 2020
    Assignee: Amgen Inc.
    Inventors: Jian Wu, Nicole Sabo, Michael De La Cruz, Gregory Flynn
  • Treatment of asthma with anti-TSLP antibody
    Patent number: 10828365
    Abstract: The present disclosure, relates, in general, to methods of treating asthma, including severe asthma and eosinophilic asthma, using an antibody specific for thymic stromal lymphopoietin (TSLP).
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: November 10, 2020
    Assignee: AMGEN INC.
    Inventors: Jane R. Parnes, Janet Griffiths
  • Compounds that inhibit Mcl-1 protein
    Patent number: 10821115
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: November 3, 2020
    Assignee: AMGEN INC.
    Inventors: Paul E. Harrington, Kate Ashton, Sean P. Brown, Matthew R. Kaller, Todd J. Kohn, Brian Alan Lanman, Kexue Li, Yunxiao Li, Jonathan D. Low, Ana Elena Minatti, Alexander J. Pickrell, Markian M. Stec, Joshua Taygerly